CN114929197A - 高亲脂性生理活性物质的控释制剂 - Google Patents

高亲脂性生理活性物质的控释制剂 Download PDF

Info

Publication number
CN114929197A
CN114929197A CN202080072481.0A CN202080072481A CN114929197A CN 114929197 A CN114929197 A CN 114929197A CN 202080072481 A CN202080072481 A CN 202080072481A CN 114929197 A CN114929197 A CN 114929197A
Authority
CN
China
Prior art keywords
physiologically active
product according
highly lipophilic
active substance
cannabinoids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080072481.0A
Other languages
English (en)
Chinese (zh)
Inventor
M·诺瓦克
J·J·诺瓦克
A·格拉维
M·文泽拉夫
S·巴托尔德
C·冈格林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ed Advanced Drug Delivery Technology Co ltd
Original Assignee
Ed Advanced Drug Delivery Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ed Advanced Drug Delivery Technology Co ltd filed Critical Ed Advanced Drug Delivery Technology Co ltd
Publication of CN114929197A publication Critical patent/CN114929197A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/658Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202080072481.0A 2019-10-16 2020-10-16 高亲脂性生理活性物质的控释制剂 Pending CN114929197A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19203549.1A EP3808336A1 (de) 2019-10-16 2019-10-16 Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen
EP19203549.1 2019-10-16
PCT/EP2020/079244 WO2021074399A1 (de) 2019-10-16 2020-10-16 Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen

Publications (1)

Publication Number Publication Date
CN114929197A true CN114929197A (zh) 2022-08-19

Family

ID=68281165

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080072481.0A Pending CN114929197A (zh) 2019-10-16 2020-10-16 高亲脂性生理活性物质的控释制剂

Country Status (10)

Country Link
US (1) US20240148758A1 (https=)
EP (2) EP3808336A1 (https=)
JP (2) JP7850068B2 (https=)
CN (1) CN114929197A (https=)
AU (1) AU2020366134B2 (https=)
BR (1) BR112022006678A2 (https=)
CA (1) CA3157693A1 (https=)
IL (1) IL292019A (https=)
MX (1) MX2022004522A (https=)
WO (1) WO2021074399A1 (https=)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
CN1287484A (zh) * 1998-08-27 2001-03-14 法玛西雅和厄普约翰公司 控释给药托耳替罗地的治疗制剂
CN1658840A (zh) * 2002-06-14 2005-08-24 Lts罗曼治疗方法有限公司 用于给予大麻制剂的薄膜形粘膜粘性的给药剂型
WO2008021394A2 (en) * 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
WO2008024490A2 (en) * 2006-08-24 2008-02-28 Theraquest Biosciences, Inc. Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
US20130338220A1 (en) * 2010-10-05 2013-12-19 Mark Tepper Compositions, dosages, and methods of using tetrahydrocannabinol derivatives
CN114945353A (zh) * 2019-10-16 2022-08-26 埃德先进药物输送技术有限责任公司 高亲脂性生理活性物质的控释制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014340709B2 (en) 2013-10-29 2019-07-04 Echo Pharmaceuticals B.V. Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders
WO2018035030A1 (en) 2016-08-15 2018-02-22 Corr-Jensen Inc. Time release fat-soluble actives

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
CN1287484A (zh) * 1998-08-27 2001-03-14 法玛西雅和厄普约翰公司 控释给药托耳替罗地的治疗制剂
CN1658840A (zh) * 2002-06-14 2005-08-24 Lts罗曼治疗方法有限公司 用于给予大麻制剂的薄膜形粘膜粘性的给药剂型
WO2008021394A2 (en) * 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
WO2008024490A2 (en) * 2006-08-24 2008-02-28 Theraquest Biosciences, Inc. Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
US20130338220A1 (en) * 2010-10-05 2013-12-19 Mark Tepper Compositions, dosages, and methods of using tetrahydrocannabinol derivatives
CN114945353A (zh) * 2019-10-16 2022-08-26 埃德先进药物输送技术有限责任公司 高亲脂性生理活性物质的控释制剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A. AKHGARI等: "Combination of time-dependent and pH-dependent polymethacrylates as a single coating formulation for colonic delivery of indomethacin pellets", 《INTERNATIONAL JOURNAL OF PHARMACEUTIC》, vol. 320, no. 1, 13 May 2006 (2006-05-13), pages 137 - 142 *
C.A. GILLIGAN等: "Factors affecting drug release from a pellet system coated with an aqueous colloidal dispersion", 《INTERNATIONAL JOURNAL OF PHARMACEUTICS》, vol. 73, no. 1, 30 June 1991 (1991-06-30), pages 51 - 68 *

Also Published As

Publication number Publication date
JP2022553652A (ja) 2022-12-26
JP2026034780A (ja) 2026-02-27
AU2020366134A1 (en) 2022-05-26
MX2022004522A (es) 2022-09-19
IL292019A (en) 2022-06-01
CA3157693A1 (en) 2021-04-22
US20240148758A1 (en) 2024-05-09
JP7850068B2 (ja) 2026-04-22
EP4045007A1 (de) 2022-08-24
EP3808336A1 (de) 2021-04-21
AU2020366134B2 (en) 2026-04-23
WO2021074399A1 (de) 2021-04-22
BR112022006678A2 (pt) 2022-07-12

Similar Documents

Publication Publication Date Title
AU2020282638B2 (en) Cannabinoid formulations
JP2025182116A (ja) 高親油性生理活性物質の放出制御製剤
WO2021228365A1 (en) Uses and formulations of cannabinoids
AU2022349666B2 (en) Cannabinoid formulation for oral administration
CN114929197A (zh) 高亲脂性生理活性物质的控释制剂
US20180263954A1 (en) Sustained Release Cannabinoid Formulations
WO2022219198A1 (en) Formulations of cannabinoids
CN115843245A (zh) 大麻素的用途和制剂
EP4074307B1 (en) Formulations of cannabinoids
CN117715626A (zh) 大麻素的制剂
CA3005885A1 (en) Sustained release cannabinoid pellets

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination